- Home
- QNST vs ENGN Comparison
QNST vs ENGN Comparison
Compare QNST & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QNST | ENGN |
|---|---|---|
| Founded | 1999 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 679.9M | 647.1M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | QNST | ENGN |
|---|---|---|
| Price | $11.53 | $7.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $24.75 | $21.00 |
| AVG Volume (30 Days) | ★ 734.4K | 521.9K |
| Earning Date | 05-06-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $282,140,000.00 | N/A |
| Revenue This Year | $18.59 | N/A |
| Revenue Next Year | $14.96 | N/A |
| P/E Ratio | $12.80 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.29 | $2.66 |
| 52 Week High | $19.53 | $12.25 |
Technical Indicators
Market Signals| Indicator | QNST | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 33.99 |
| Support Level | $10.54 | $6.18 |
| Resistance Level | $15.52 | $7.33 |
| Average True Range (ATR) | 0.50 | 0.64 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 16.79 | 16.62 |
Price Performance
Historical ComparisonAbout QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.